ELAN

Elanco Animal Health Inc (ELAN) | Rumor.io

Elanco Animal Health

ELAN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,655

Bullish sentiment (50-day avg)91%

Price to earnings ratio377.1

Market capitalization11.2B

Earnings per share-0.41

Dividend yield (TTM)—

Revenue (annual)4.7B

Net income (annual)-232M

Social

What share of all stock conversation is about ELAN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

May 7

Elanco Animal Health has boosted its adjusted earnings per share forecast for the full year.
The company's CEO, Jeff Simmons, attributes the pet care market's performance to Elanco's company earnings.
Elanco Animal Health's stock price has surged 182% with a massive volume of 6.3M shares traded, reaching $22.99.

Generated by AI

Sentiment

Of the messages about ELAN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +7.69	85.19% -7.84
Bearish	—	—	0% -7.69	14.81% +7.84

Aug 9

Elanco Animal Health Incorporated exceeded its Q2 revenue guidance, increasing its full-year 2021 revenue guidance for the third time.
The company's earnings of $0.28 beat the consensus estimate of $0.26, indicating a strong financial performance.
Analysts are mildly confident in Elanco, with a 80% buy consensus among 8 analysts, and the stock is considered undervalued at $30.

Generated by AI

Topics

Of the messages about ELAN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	64.1%	8.59%
Technical Analysis	—	0%	35.9%	1.09%
Macro	—	0%	0%	1.5%
Earnings	—	0%	0%	4.52%
Analysts	—	0%	0%	83.72%
Controversies	—	0%	0%	0.58%

Earnings· Aug 8

Elanco Animal Health reported Q2 2022 earnings of $0.36 per share, exceeding the consensus estimate of $0.26.
The company reported revenue of $1.177 billion for Q2 2022, in line with expectations.
Elanco Animal Health lowered its FY22 guidance to $1.06-1.13 EPS and revenue guidance to $4.465-4.55 billion, citing macro challenges and topline pressures.

Announcements· Feb 5

Elanco Animal Health Incorporated (ELAN) has agreed to sell its aqua business to Merck for $1.3 billion in cash.
The sale is expected to generate approximately $175 million in annual revenue for Merck's animal health business.
Elanco plans to use the proceeds from the sale to pay down debt, with the company's shares trading higher following the announcement.

Generated by AI

Community

Of the messages about ELAN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	85%	29.17%	8.8%
Newcomers	100%	15%	70.83%	91.2%

Regulars· Feb 24

Elanco Animal Health reports Q4-25 results, with 9% organic CC growth and 10th straight quarter of underlying expansion, driven by innovation and solid growth.
The company's restructuring charges weighed on GAAP, but operating momentum remains intact, with adjusted EPS of $0.13 and revenue of $1.14B.
Elanco's Q4-25 results beat estimates, with revenue exceeding expectations by $51.6M and EPS beating estimates by $0.02, despite a -50.00% YoY decline.

Newcomers· May 7

Elanco Animal Health has boosted its adjusted earnings per share forecast for the full year, with the company's CEO discussing the pet care market's performance.
Newcomers to the Elanco Animal Health stock are focused on the company's earnings growth and its potential impact on the pet care industry.
The company's CEO, Jeff Simmons, is highlighted as a key figure in the discussion, with his comments on the company's earnings and the pet care market sparking interest among newcomers.

Generated by AI

Elanco Animal Health (NYSE:ELAN) President and CEO Jeff Simmons outlined the company’s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. Simmons said Elanco delivered 10% report

4d agoYahoo Finance

Elanco at Bank of America Global Healthcare Conference: growth, pipeline

7d agoInvesting.com

Stifel reiterates Elanco Animal Health stock rating on Befrena outlook

11d agoInvesting.com

Elanco to Participate in BofA Securities Global Healthcare Conference 2026

Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026. Jeff Simmons, president and CEO, will participate in a fireside chat on Tuesday, September 22 at 2:10 p.m. BST (9:10 a.m. EDT).

12d agoYahoo Finance Singapore

Is Elanco Animal Health (ELAN) Undervalued As Growth Expectations Meet A Recent Pullback?

Elanco Animal Health (ELAN) drew fresh attention after its latest closing price of US$23.17. This put recent share moves and the company’s improving annual revenue and net income figures in sharper focus for investors. Recent moves show mixed momentum for Elanco Animal Health, with a 1-day share price return of 1.36% but a 7-day share price return down 5.43%. However, the 1-year total shareholder return of 24.30% and 3-year total shareholder return of 96.36% point to a much stronger...

15d agoYahoo Finance UK

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

18d agoYahoo Finance

Also Discussed

Investors talking about ELAN also mention

#	Name	Attention
1	Zoetis Inc. Class A Common StockZTS	0.03%+0.02
2	IDEXX Laboratories, Inc.IDXX	0%0
3	PETQ - PetIQ, Inc.	——
4	TuHURA Biosciences, Inc.HURA	0%0
5	OneMedNet Corp. Class A Common StockONMD	0.02%+0.02
6	Allied Gaming & Entertainment Inc.AGAE	0%0
7	Deluxe CorpDLX	0%new
8	BHIL - Benson Hill, Inc.	——
9	Radware Ltd.RDWR	0%new
10	Ohmyhome Ltd. Class AOMH	0%new

Elanco Animal Health Inc

Healthcare
Drug Manufacturers - Specialty & Generic

Elanco Animal Health Incorporated is an animal health company focused on developing, manufacturing, and marketing products for pets and farm animals. Its portfolio includes treatments and preventive solutions for parasitic control, dermatology, pain management, vaccines, and other therapeutic areas used in companion animals and livestock. The company serves veterinarians, pet owners, farmers, and producers across a wide range of species, including dogs, cats, cattle, poultry, swine, and sheep. Elanco Animal Health Incorporated also offers products used in food-animal health and production settings, supporting disease prevention and animal wellbeing in everyday care and commercial agriculture. Headquartered in Indianapolis, Indiana, Elanco Animal Health Incorporated operates as a diversified participant in the global animal health market, with a broad product mix spanning companion animal and farm animal care.

Website

Location

450 Elanco Circle

Indianapolis, IN, 46221

United States

Social

What share of all stock conversation is about ELAN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

May 7

Elanco Animal Health has boosted its adjusted earnings per share forecast for the full year.
The company's CEO, Jeff Simmons, attributes the pet care market's performance to Elanco's company earnings.
Elanco Animal Health's stock price has surged 182% with a massive volume of 6.3M shares traded, reaching $22.99.

Generated by AI

Sentiment

Of the messages about ELAN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +7.69	85.19% -7.84
Bearish	—	—	0% -7.69	14.81% +7.84

Aug 9

Elanco Animal Health Incorporated exceeded its Q2 revenue guidance, increasing its full-year 2021 revenue guidance for the third time.
The company's earnings of $0.28 beat the consensus estimate of $0.26, indicating a strong financial performance.
Analysts are mildly confident in Elanco, with a 80% buy consensus among 8 analysts, and the stock is considered undervalued at $30.

Generated by AI

Topics

Of the messages about ELAN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	64.1%	8.59%
Technical Analysis	—	0%	35.9%	1.09%
Macro	—	0%	0%	1.5%
Earnings	—	0%	0%	4.52%
Analysts	—	0%	0%	83.72%
Controversies	—	0%	0%	0.58%

Earnings· Aug 8

Elanco Animal Health reported Q2 2022 earnings of $0.36 per share, exceeding the consensus estimate of $0.26.
The company reported revenue of $1.177 billion for Q2 2022, in line with expectations.
Elanco Animal Health lowered its FY22 guidance to $1.06-1.13 EPS and revenue guidance to $4.465-4.55 billion, citing macro challenges and topline pressures.

Announcements· Feb 5

Elanco Animal Health Incorporated (ELAN) has agreed to sell its aqua business to Merck for $1.3 billion in cash.
The sale is expected to generate approximately $175 million in annual revenue for Merck's animal health business.
Elanco plans to use the proceeds from the sale to pay down debt, with the company's shares trading higher following the announcement.

Generated by AI

Community

Of the messages about ELAN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	85%	29.17%	8.8%
Newcomers	100%	15%	70.83%	91.2%

Regulars· Feb 24

Elanco Animal Health reports Q4-25 results, with 9% organic CC growth and 10th straight quarter of underlying expansion, driven by innovation and solid growth.
The company's restructuring charges weighed on GAAP, but operating momentum remains intact, with adjusted EPS of $0.13 and revenue of $1.14B.
Elanco's Q4-25 results beat estimates, with revenue exceeding expectations by $51.6M and EPS beating estimates by $0.02, despite a -50.00% YoY decline.

Newcomers· May 7

Elanco Animal Health has boosted its adjusted earnings per share forecast for the full year, with the company's CEO discussing the pet care market's performance.
Newcomers to the Elanco Animal Health stock are focused on the company's earnings growth and its potential impact on the pet care industry.
The company's CEO, Jeff Simmons, is highlighted as a key figure in the discussion, with his comments on the company's earnings and the pet care market sparking interest among newcomers.

Generated by AI

Elanco Animal Health

Social

May 7

Sentiment

Aug 9

Topics

Earnings· Aug 8

Announcements· Feb 5

Community

Regulars· Feb 24

Newcomers· May 7

News

Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground

Elanco at Bank of America Global Healthcare Conference: growth, pipeline

Stifel reiterates Elanco Animal Health stock rating on Befrena outlook

Elanco to Participate in BofA Securities Global Healthcare Conference 2026

Is Elanco Animal Health (ELAN) Undervalued As Growth Expectations Meet A Recent Pullback?

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

Also Discussed

Elanco Animal Health Inc

Company Information

Location

News

Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground

Elanco at Bank of America Global Healthcare Conference: growth, pipeline

Stifel reiterates Elanco Animal Health stock rating on Befrena outlook

Elanco to Participate in BofA Securities Global Healthcare Conference 2026

Is Elanco Animal Health (ELAN) Undervalued As Growth Expectations Meet A Recent Pullback?

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

Also Discussed

Social

May 7

Sentiment

Aug 9

Topics

Earnings· Aug 8

Announcements· Feb 5

Community

Regulars· Feb 24

Newcomers· May 7